Doctors Note Logo

Published on: 8/18/2026

How to Interpret Fibroblast Growth Factor 23 Blood Tests with an Endocrinologist

Fibroblast growth factor 23 (FGF23) results only make sense when read beside phosphate, calcium, PTH, v

answer background

Explanation

How to Interpret Fibroblast Growth Factor 23 Blood Tests with an Endocrinologist

Fibroblast Growth Factor 23 (FGF23) is a hormone produced by bone cells that helps regulate phosphate and vitamin D levels in your blood. Measuring serum intact FGF23 can help your endocrinologist identify disorders of phosphate metabolism. This guide explains what FGF23 does, when to test it, how to interpret your serum intact FGF23 reference ranges, and what to discuss with your doctor.


1. Why Measure FGF23?

  • FGF23 controls how much phosphate your kidneys reabsorb.
  • It lowers active vitamin D (calcitriol) production.
  • Imbalances can lead to weak bones, kidney stones, or chronic kidney disease (CKD) complications.

Your endocrinologist may order a serum intact FGF23 test if you have unexplained low or high phosphate levels, bone pain, muscle weakness, or signs of CKD.


2. Understanding Serum Intact FGF23

“Intact” FGF23 refers to the full, biologically active molecule. Unlike assays that detect fragments, an intact FGF23 assay better reflects what’s happening in your body.

Key points:

  • It’s measured in picograms per milliliter (pg/mL).
  • Results can vary by lab method; always compare to the lab’s own reference range.
  • Timing: fasting samples are often preferred to reduce variability.

3. Serum Intact FGF23 Reference Ranges

Reference ranges can differ slightly among laboratories, but typical values are:

  • Adults: 20–60 pg/mL
  • Children: 30–100 pg/mL (due to higher bone turnover)

When reviewing your report, look for the lab-specific range labeled “reference interval.” Always discuss any value outside that interval with your endocrinologist.


4. Indications for Testing

Your doctor may recommend an FGF23 test if you have:

  • Persistent low serum phosphate (hypophosphatemia)
  • Elevated phosphate (hyperphosphatemia), especially in CKD
  • Bone pain, fractures, or muscle weakness
  • Suspected genetic disorders affecting phosphate (e.g., X-linked hypophosphatemia)
  • Monitoring of treatment with phosphate binders or active vitamin D analogs

5. Interpreting Elevated FGF23 Levels

High serum intact FGF23 suggests that your body is trying to eliminate excess phosphate or compensate for high vitamin D:

Possible causes:

  • Chronic kidney disease (CKD): Damaged kidneys reduce phosphate excretion, triggering FGF23 rise.
  • Tumor-induced osteomalacia: Rare tumors secrete FGF23, causing phosphate loss.
  • Genetic hypophosphatemic rickets: Mutations elevate FGF23 production.

Clinical considerations:

  • In CKD, rising FGF23 is an early marker of phosphate imbalance, even before phosphate itself climbs.
  • Very high levels (>100 pg/mL in adults) warrant imaging studies to localize potential tumors.

6. Interpreting Low FGF23 Levels

Low FGF23 suggests your kidneys are conserving phosphate or there’s low vitamin D activity:

Possible causes:

  • Familial tumoral calcinosis: Rare condition leading to phosphate retention.
  • Vitamin D deficiency: Low calcitriol reduces FGF23 feedback.
  • Hypoparathyroidism: Low parathyroid hormone can indirectly lower FGF23.

Clinical considerations:

  • Low levels (<20 pg/mL in adults) alongside high phosphate may point to phosphate-wasting disorders.
  • Further testing—parathyroid hormone (PTH), 25-hydroxyvitamin D, and kidney imaging—helps to clarify the diagnosis.

7. Working with Your Endocrinologist

Interpreting FGF23 is complex. Here’s how you and your doctor can work together:

  1. Review your medical history
    • CKD stage, family history of bone disorders, prior fractures.
  2. Order complementary tests
    • Serum phosphate, calcium, PTH, 25-hydroxy and 1,25-dihydroxyvitamin D.
    • Urinary phosphate excretion (fractional excretion of phosphate).
  3. Assess medications
    • Phosphate binders, vitamin D analogs, diuretics can alter results.
  4. Plan imaging studies
    • Bone scans or whole-body MRI if tumor-induced osteomalacia is suspected.
  5. Develop a treatment plan
    • May include phosphate supplements, active vitamin D, or tumor removal.

8. Questions to Ask Your Doctor

  • What is my serum intact FGF23 result, and how does it compare to the reference range?
  • Could my current medications affect my FGF23 level?
  • Are additional tests needed to confirm the diagnosis?
  • What are the treatment goals for my condition?
  • How often should I repeat the FGF23 test?

9. Tracking Your Symptoms

Understanding your symptoms helps guide diagnosis. You might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to organize your concerns before your appointment.


10. When to Seek Immediate Help

While FGF23 testing itself is low-risk, some related symptoms may signal serious issues. Contact a healthcare professional right away if you experience:

  • Severe muscle cramps or spasms
  • Sudden, severe bone pain or fractures
  • Signs of low blood calcium (numbness, tingling around the mouth)
  • Rapidly worsening kidney function (low urine output, swelling)

11. Key Takeaways

  • Serum intact FGF23 is a precise marker of phosphate regulation.
  • Reference ranges: 20–60 pg/mL in adults; check your lab’s interval.
  • High levels often link to CKD, genetic rickets, or tumors.
  • Low levels may indicate phosphate retention disorders or vitamin D issues.
  • Interpretation requires correlation with phosphate, calcium, PTH, and vitamin D tests.
  • Work closely with your endocrinologist to plan further tests and treatment.
  • Use the Ubie Symptom Checker to track symptoms before your visit.
  • Always speak to a doctor about any potentially life-threatening or serious concerns.

Your health is a partnership. Discuss your test results in detail with your endocrinologist or primary care provider to ensure accurate diagnosis and safe management. If you notice any severe or sudden symptoms, seek medical attention immediately.

(References)

  • * Bonewald LF, Wacker MJ. FGF23 production by osteocytes. Pediatr Nephrol. 2013 Apr;28(4):563-8. doi: 10.1007/s00467-012-2309-3. Epub 2012 Sep 16. PMID: 22983423; PMCID: PMC3582753.

  • * Smith ER, McMahon LP, Holt SG. Fibroblast growth factor 23. Ann Clin Biochem. 2014 Mar;51(Pt 2):203-27. doi: 10.1177/0004563213510708. Epub 2013 Nov 22. PMID: 24269946.

  • * Fukumoto S. Anti-fibroblast growth factor 23 antibody therapy. Curr Opin Nephrol Hypertens. 2014 Jul;23(4):346-51. doi: 10.1097/01.mnh.0000447012.98357.da. PMID: 24848934.

  • * Kuczera P, Adamczak M, Wiecek A. Fibroblast Growth Factor-23-A Potential Uremic Toxin. Toxins (Basel). 2016 Dec 8;8(12). doi: 10.3390/toxins8120369. Epub 2016 Dec 8. PMID: 27941640; PMCID: PMC5198563.

  • * Fauconnier C, Roy T, Gillerot G, Roy C, Pouleur AC, Gruson D. FGF23: Clinical usefulness and analytical evolution. Clin Biochem. 2019 Apr;66:1-12. doi: 10.1016/j.clinbiochem.2019.03.002. Epub 2019 Mar 7. PMID: 30853324.

  • * Simic P, Babitt JL, Rhee EP. Glycerol-3-phosphate and fibroblast growth factor 23 regulation. Curr Opin Nephrol Hypertens. 2021 Jul 1;30(4):397-403. doi: 10.1097/MNH.0000000000000715. PMID: 33901058; PMCID: PMC8312345.

  • * Ivey-Miranda JB, Stewart B, Cox ZL, McCallum W, Maulion C, Gleason O, Meegan G, Amatruda JG, Moreno-Villagomez J, Mahoney D, Turner JM, Wilson FP, Estrella MM, Shlipak MG, Rao VS, Testani JM. FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions. Circ Heart Fail. 2021 Nov;14(11):e008385. doi: 10.1161/CIRCHEARTFAILURE.121.008385. Epub 2021 Oct 25. PMID: 34689571; PMCID: PMC8782627.

  • * Simic P, Babitt JL. Regulation of FGF23: Beyond Bone. Curr Osteoporos Rep. 2021 Dec;19(6):563-573. doi: 10.1007/s11914-021-00703-w. Epub 2021 Nov 10. PMID: 34757587; PMCID: PMC8958553.

  • * Ito N, Hidaka N, Kato H. Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia. Endocrinol Metab (Seoul). 2024 Apr;39(2):255-261. doi: 10.3803/EnM.2023.1908. Epub 2024 Mar 11. PMID: 38467164; PMCID: PMC11066443.

  • * Takashi Y, Kawanami D, Fukumoto S. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders. Curr Opin Endocrinol Diabetes Obes. 2024 Aug 1;31(4):170-175. doi: 10.1097/MED.0000000000000866. Epub 2024 Apr 30. PMID: 38687287.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.